Modality
Multispecific
MOA
Cl18.2
Target
KRASG12C
Pathway
Wnt
GBMUrothelial CaThymoma
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
Aug 2021
→ Jun 2031
Phase 1Current
NCT05386593
2,266 pts·GBM
2021-08→2031-06·Active
NCT08761980
1,812 pts·GBM
2025-01→2027-06·Not yet recruiting
4,078 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-06-171.2y awayPh2 Data· GBM
2031-06-235.2y awayPh2 Data· GBM
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Active
P1/2
Not yet…
Catalysts
Ph2 Data
2027-06-17 · 1.2y away
GBM
Ph2 Data
2031-06-23 · 5.2y away
GBM
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05386593 | Phase 1/2 | GBM | Active | 2266 | PASI75 |
| NCT08761980 | Phase 1/2 | GBM | Not yet recr... | 1812 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C |